Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms
Open Access
- 15 September 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e24397
Abstract
Cancer stem cells (CSCs) possess high tumor-initiating capacity and have been reported to be resistant to therapeutics. Vice versa, therapy-resistant cancer cells seem to manifest CSC phenotypes and properties. It has been generally assumed that drug-resistant cancer cells may all be CSCs although the generality of this assumption is unknown. Here, we chronically treated Du145 prostate cancer cells with etoposide, paclitaxel and some experimental drugs (i.e., staurosporine and 2 paclitaxel analogs), which led to populations of drug-tolerant cells (DTCs). Surprisingly, these DTCs, when implanted either subcutaneously or orthotopically into NOD/SCID mice, exhibited much reduced tumorigenicity or were even non-tumorigenic. Drug-tolerant DLD1 colon cancer cells selected by a similar chronic selection protocol also displayed reduced tumorigenicity whereas drug-tolerant UC14 bladder cancer cells demonstrated either increased or decreased tumor-regenerating capacity. Drug-tolerant Du145 cells demonstrated low proliferative and clonogenic potential and were virtually devoid of CD44+ cells. Prospective knockdown of CD44 in Du145 cells inhibited cell proliferation and tumor regeneration, whereas restoration of CD44 expression in drug-tolerant Du145 cells increased cell proliferation and partially increased tumorigenicity. Interestingly, drug-tolerant Du145 cells showed both increases and decreases in many “stemness” genes. Finally, evidence was provided that chronic drug exposure generated DTCs via epigenetic mechanisms involving molecules such as CD44 and KDM5A. Our results thus reveal that 1) not all DTCs are necessarily CSCs; 2) conventional chemotherapeutic drugs such as taxol and etoposide may directly target CD44+ tumor-initiating cells; and 3) DTCs generated via chronic drug selection involve epigenetic mechanisms.Keywords
This publication has 64 references indexed in Scilit:
- NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivationOncogene, 2011
- PC3 Human Prostate Carcinoma Cell Holoclones Contain Self-renewing Tumor-Initiating CellsCancer Research, 2008
- Significance of CD90+ Cancer Stem Cells in Human Liver CancerCancer Cell, 2008
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug ResistanceCancer Research, 2008
- let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer CellsCell, 2007
- Identification and expansion of the tumorigenic lung cancer stem cell populationCell Death & Differentiation, 2007
- CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathwayOncogene, 2007
- Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic CancerCell Stem Cell, 2007
- Hierarchical Organization of Prostate Cancer Cells in Xenograft Tumors: The CD44+α2β1+ Cell Population Is Enriched in Tumor-Initiating CellsCancer Research, 2007
- Phenotypic characterization of human colorectal cancer stem cellsProceedings of the National Academy of Sciences, 2007